Ramipril Capsule
Product Images NDC 70518-4607

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Ramipril (NDC 70518-4607). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Mm1 (Ramipril 5mg 70518 4607 00)

This is product information for Ramipril Capsules manufactured by Rising Pharma, Inc. The usual dosage instructions are included on the insert. The medication should be kept away from children and stored at a controlled room temperature of 20-25°C (68-77°F), with excursions permitted to 15-30°C (59-86°F). Each box contains 50 capsules. The product was repackaged by RemedyRepack in Indiana, PA.*

FDA Label Image

Remedy_label (Remedy Label)

This is a description of a Ramipril Capsule manufactured by Rising Pharma, Inc. The medication is in a capsule form with a dosage of 5mg. The manufacturer's location is Allendale, NJ 07401. The text also provides information on storage conditions, dosage instructions, and contact details for repackaging by RemedyRepack Inc. RX Only.*

FDA Label Image

Figure 1 (Ramipril Fig1)

This data shows the proportion of patients under Ramipril treatment over a period of time (measured in days). The percentage of patients under Ramipril varies at different time points, with the highest being 0.2 and the lowest being 0.0. The data suggests a significant change in patient distribution over time, with a p-value of 0.0001 indicating statistical significance. This information is crucial for analyzing the effectiveness and impact of Ramipril treatment on patients.*

FDA Label Image

Figure 2 (Ramipril Fig2)

This document appears to be a detailed comparison of different cardiovascular and risk factors in patients, including data related to diabetes, age, sex, hypertension, prior medical history, and incidence of outcomes in the placebo group. It utilizes categories such as cardiovascular disease, diabetes, age, sex, hypertension, history of coronary artery disease, among others to present information on the number of patients in different subgroups and the incidence of composite outcomes in the placebo group. This data may be utilized for research or clinical purposes to assess relative risks and outcomes in different patient populations.*

FDA Label Image

Chemical Structure (Ramipril Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.